title: Comparative speed of kill of sarolaner (Simparica) and afoxolaner (NexGard) against induced infestations of Amblyomma americanum on dogs.
abstract: BACKGROUND
  The lone star tick, Amblyomma americanum, infests dogs and cats in North America and is the vector of the pathogens that cause monocytic and granulocytic ehrlichiosis in dogs and humans. A parasiticide's speed of kill is important to minimize the direct and deleterious effects of tick infestation and especially to reduce the risk of transmission of tick-borne pathogens. In this study, speed of kill of a novel orally administered isoxazoline parasiticide, sarolaner (Simparica chewable tablets), against A. americanum on dogs was evaluated and compared with afoxolaner (NexGard) for 5 weeks following a single oral dose.
  
  
  METHODS
  Based on pretreatment tick counts, 24 dogs were randomly allocated to treatment with sarolaner (2 to 4 mg/kg), afoxolaner (2.5 to 6.8 mg/kg) or a placebo. Dogs were examined and live ticks counted at 8, 12, and 24 h after treatment and subsequent re-infestations on Days 7, 14, 21, 28, and 35. Efficacy was determined at each time point relative to counts for placebo dogs.
  
  
  RESULTS
  A single oral dose of sarolaner provided 100 % efficacy within 24 h of treatment, and consistently provided >90% efficacy against subsequent weekly re-infestations with ticks to Day 28. Significantly more live ticks were recovered from afoxolaner-treated dogs than from sarolaner-treated dogs at 24 h after infestation from Day 7 through Day 35 (P ≤ 0.0247). At 24 h, efficacy of afoxolaner declined to less than 90% from Day 14 to the end of the study. There were no adverse reactions to treatment.
  
  
  CONCLUSIONS
  In this controlled laboratory evaluation, sarolaner had a faster speed of kill against A. americanum ticks than afoxolaner. The rapid and consistent kill of ticks by sarolaner within 24 h after a single oral dose over 28 days, suggests this treatment will provide highly effective and reliable control of ticks over the entire treatment interval, and could help reduce the risk of transmission of tick-borne pathogens by A. americanum.
authors.affiliation: Zoetis, Veterinary Medicine Research and Development, 333 Portage St, Kalamazoo, MI, 49007, USA. robert.six@zoetis.com.
authors.forename: Robert H
authors.initials: RH
authors.lastname: Six
authors.affiliation: BerTek, Inc., PO Box 606, Greenbrier, AR, 72058, USA. wreverett@bertekconsults.com.
authors.forename: William R
authors.initials: WR
authors.lastname: Everett
authors.affiliation: Zoetis, Veterinary Medicine Research and Development, 333 Portage St, Kalamazoo, MI, 49007, USA. sara.chapin@zoetis.com.
authors.forename: Sara
authors.initials: S
authors.lastname: Chapin
authors.affiliation: Zoetis, Veterinary Medicine Research and Development, 333 Portage St, Kalamazoo, MI, 49007, USA. sean.mahabir@zoetis.com.
authors.forename: Sean P
authors.initials: SP
authors.lastname: Mahabir
mesh_terms: D056810:Acaricides / Q000008:administration & dosage*; D000284:Administration, Oral; D000818:Animals; D004195:Disease Models, Animal; D004285:Dogs; D007555:Isoxazoles / Q000008:administration & dosage; D026863:Ixodidae / Q000187:drug effects*; D059208:Parasite Load; D010919:Placebos / Q000008:administration & dosage; D013984:Tick Infestations / Q000188:drug therapy*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D056810:Acaricides; D007555:Isoxazoles; D010919:Placebos